Investor Presentation: First Nine Months of 2020
99
Investor presentation
First nine months of 2020
US insulin net prices have declined in recent years, yet some
patients still struggle with affordability
The US population by health
insurance coverage
Private insurance schemes
Uninsured
Government insurance schemes
List price and net price
development for NovoLogⓇvial
List price¹
Net price¹
Novo Nordisk insulin affordability
offerings in the US
Novo NordiskⓇ
48%
8%
333 million people
600
500
44%
400
Note: Government insurance schemes cover Medicare, Medicaid and public
exchanges - some of these with high deductibles
Source: Census.gov; Congressional Budget Office Health Insurance Coverage 2016-
2026; Medicare Enrollment Dashboard; CMS Health Insurance Enrollment Projection
2015-2025; Medicaid and CHIP Enrollment Report Oct 2017; CMS Insurance
Marketplace Fact sheet 2017; CDC.gov
300
200
100
0
2001
2002
2003
2004
2005
2006
2007
2008
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
1 Adjusted for inflation
ZIOZ
2 Y-axis represents annual list and net price indices adjusted for
CPI-U
2019
•
•
•
Follow-on brand fast-acting (NovologⓇ) and premix
insulin (NovologⓇ Mix) with 50% list price discount vs.
branded versions
My$99Insulin 30-day supply of a combination of Novo
Nordisk insulin products (up to 3 vials or 2 packs of
pens) for USD 99
Patient Assistance Program free diabetes medication
to people in need, annual income <400% above
government defined poverty. Program expanded
during COVID-19 outbreak if job loss and limited
coverage
Human insulin for about USD25/vial at national
pharmacies, including Walmart and CVS
Immediate Supply a short-term, immediate-need
program offering free insulin for those at risk of
rationing while working to identify a longer-term
solution
Co-pay Savings Cards providing USD -250 million in
assistance in 2019View entire presentation